Waters (WAT) is back in focus after recent share price moves that contrast with its year to date decline, prompting investors to reassess the stock’s valuation and operating profile.

The recent pullback, with a 1-day share price return of a 0.55% decline and a 7-day share price return of a 3.92% decline from US$363.34, sits against a 90-day share price return of 21.26% and a 3-year total shareholder return of 41.42%. This indicates that long term momentum has been stronger than the more recent drift.

If Waters’s moves have you rethinking where growth could come from next, it may be worth scanning opportunities in AI infrastructure and computing by checking out 48 AI infrastructure stocks

With Waters trading around US$363.34, a reported 24.80% intrinsic discount and a roughly 10% gap to analyst targets raise a key question for you: is there genuine upside here, or is future growth already priced in?

Most Popular Narrative: 7.6% Undervalued

At about $363.34, Waters trades below the most followed fair value estimate of $393.14, putting the spotlight on what is driving that gap.

Recurring revenues are accelerating (up 11% this quarter), underpinned by expanding service plan attachments and e-commerce adoption, which enhances revenue stability and net margins, setting up the combined company for more resilient earnings across CapEx cycles.

Curious what underpins that valuation call? Consider factors such as faster top line growth, shifting profit margins, and a richer mix of recurring earnings shaping those long term cash flow assumptions.

All of this sits within a detailed model that applies a 7.9% discount rate and incorporates specific paths for revenue, earnings and future valuation multiples. It is worth comparing those assumptions with your own before relying on the $393.14 figure as your anchor.

Result: Fair Value of $393.14 (UNDERVALUED)

However, that upside story still faces real pressure if the BD integration underdelivers on cost and revenue synergies, or if funding constraints keep weighing on academic and pharma demand.

Another View: High Multiple, Different Message

That 7.6% discount to a US$393.14 fair value sounds appealing, but the current P/E of 79.8x is far above both the Global Life Sciences average of 34.9x and a fair ratio of 30.4x. In practice, that means a lot has to go right. How comfortable are you paying up for it?

Next Steps

If this mix of risks and rewards leaves you undecided, take a closer look at the underlying data now and weigh the 2 key rewards and 3 important warning signs

Looking for more investment ideas?

Do not stop with one stock. Broaden your watchlist with fresh ideas that fit your style so you are not relying on a single bet.

• Target value by scanning companies that look mispriced on quality and fundamentals through the 48 high quality undervalued stocks.
• Prioritise durability by checking stocks that pair financial strength with conservative risk profiles using the 63 resilient stocks with low risk scores.
• Spot potential early movers by searching a 24 elite penny stocks with strong financials list that filters for stronger balance sheets and fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.